Gary Zammit, PhD, the President and CEO of Clinilabs Drug Development Corporation, has contributed to a scientific study evaluating the effect of daridorexant on sleep architecture in people with insomnia. The study examined the effects of daridorexant on hyperarousal-related features with results showing daridorexant reduced certain EEG features linked to hyperarousal. Daridorexant decreased the probability of transitioning from wakefulness to wakefulness and an improvement in spectral features associated with drowsiness and sleep during wakefulness and N1.
To read the complete article visit: Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder – A pooled post hoc analysis of two randomized Phase 3 clinical studies